Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment
https://doi.org/10.14341/omet13036
Abstract
One of the causes of non-tumor related hyperprolactinemia is taking a medications. Physicians of various specialties, such as cardiologists, gastroenterologists, endocrinologists, and neurologists, encounter hyperprolactinemia as a side effect of drug therapy in their practice, but it is most often observed in the practice of a psychiatrist when treating patients with psychotropic medications. Over the past few years, there has been an increase in the frequency of prescriptions of antidepressants and neuroleptics due to post-COVID-19 syndrome, anxiety and stress caused by the pandemic of a new coronavirus infection. There is also a predisposition to the development of hyperprolactinemia on the background of taking neuroleptics due to genetic features of patients. Currently, there is no established common algorithm for diagnosis and treatment of drug-induced hyperprolactinemia in the world. Based on a review of foreign and domestic literature, the article discusses in detail the mechanisms of development and various approaches to the correction of iatrogenic (drug-induced) hyperprolactinemia, assesses the prolactogenic activity of neuroleptics, and proposes algorithms for prolactin monitoring and correction of hyperprolactinemia using dopamine agonists. Often the tactics of management of such patients need to be discussed by a team of specialized physicians.
About the Authors
L. K. Dzeranova
Endocrinology Research Centre
Russian Federation
Russian Federation
Larisa K. Dzeranova, MD, PhD
Moscow
eLibrary SPIN: 2958-5555
S. Y. Vorotnikova
Endocrinology Research Centre
Russian Federation
Russian Federation
Svetlana Y. Vorotnikova, MD, PhD
Moscow
eLibrary SPIN: 6571-1206
A. S. Shutova
Endocrinology Research Centre
Russian Federation
Russian Federation
Aleksandra S. Shutova, MD, postgraduate student
Moscow
eLibrary SPIN: 4774-0114
E. A. Pigarova
Endocrinology Research Centre
Russian Federation
Russian Federation
Ekaterina A. Pigarova, MD, PhD
Moscow
eLibrary SPIN: 6912-6331
M. I. Yevloyeva
Endocrinology Research Centre
Russian Federation
Russian Federation
Madina I. Yevloyeva, MD, postgraduate student
11 Dm. Ulyanova street, 117036 Moscow
eLibrary SPIN: 4887-5455
References
1. di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. Pituitary. 2020;23(3):314-321. doi: https://doi.org/10.1007/s11102-020-01041-3
2. Sherman L, Fisher A, Klass E, Markowitz S. Pharmacologic Causes of Hyperprolactinemia. Semin Reprod Med. 1984;2(01):31-45. doi: https://doi.org/10.1055/s-2008-1067944
3. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in prl receptor knockout mice. Endocr Rev. 1998;19(3):225-268. doi: https://doi.org/10.1210/edrv.19.3.0334
4. Coker F, Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs. 2010;24(7):563-574. doi: https://doi.org/10.2165/11533140-000000000-00000
5. O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(S2):70-75. doi: https://doi.org/10.1177/0269881107088439
6. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(3):69-82. doi: https://doi.org/10.1016/S0306-4530(02)00128-2
7. Bushe C, Sniadecki J, Bradley A, Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol. 2010;24(7):1001-1009. doi: https://doi.org/10.1177/0269881108101783
8. Gorobets L.N., Mazo G.E. Hyperprolactinemia during application of second-generation antipsychotics: the principles of prevention, diagnosis and correction. V.M. Bekhterev review of psychiatry and medical psychology. 2017;(1):63-69. (In Russ.).
9. Rossiiskaia assotsiatsiia endokrinologov. Klinicheskie rekomendatsii. Giperprolaktinemiia. Moscow: Ministerstvo zdravookhraneniia; 2021. (In Russ.).
10. Alosaimi FD, Fallata EO, Abalhassan M, et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract. 2018;22(4):274-281. doi: https://doi.org/10.1080/13651501.2018.1425459
11. Grigg J, Worsley R, Thew C, et al. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. doi: https://doi.org/10.1007/s00213-017-4730-6
12. Iunilainen OA. Giperprolaktinemiia, assotsiirovannaia s priemom neiroleptikov: klinicheskie podkhody i vozmozhnosti terapii [dissertation]. Moscow; 2015. (In Russ.).
13. Geers LM, Pozhidaev IV, Ivanova SA, et al. Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia. Br J Clin Pharmacol. 2020;86(9):1827-1835. doi: https://doi.org/10.1111/bcp.14288
14. González-Rodríguez A, Labad J, Seeman M V. Antipsychotic-induced hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. Prog Neuro-Psychopharmacology Biol Psychiatry. 2020;(101):109941. doi: https://doi.org/10.1016/j.pnpbp.2020.109941
15. Spitzer M. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol. 1998;91(5):693-695. doi: https://doi.org/10.1016/S0029-7844(98)00066-0
16. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol Clin Exp. 2010;25(4):281-297. doi: https://doi.org/10.1002/hup.1116
17. Inder WJ, Castle D. Antipsychotic-Induced Hyperprolactinaemia. Aust New Zeal J Psychiatry. 2011;45(10):830-837. doi: https://doi.org/10.3109/00048674.2011.589044
18. Gorobets LN, Mazo G. Neuroendocrine dysfunctions during psychopharmacological treatment: clinical presentations, diagnosis, risk factors and treatment. Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 2014;114(10):122-130. (In Russ.).
19. Junilajnen OA, Starostina EG, Dzeranova LK, et al. Jepidemiologicheskie harakteristiki giperprolaktinemii, associirovannoj s priemom nejroleptikov. In: Sovremennaja terapija v psihiatrii i nevrologii. Kazan’: Izdatel’skij dom «Lotos»; 2014. Vol. 4. P. 12-23. (In Russ.).
20. Schmidt AW, Lebel LA, Howard HR, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201. doi: https://doi.org/10.1016/S0014-2999(01)01188-8
21. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133-135. doi: https://doi.org/10.1176/appi.ajp.159.1.133
22. Azorin J-M, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. doi: https://doi.org/10.1097/01.yic.0000177020.26311.a7
23. Mailman R, Murthy V. Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488-501. doi: https://doi.org/10.2174/138161210790361461
24. Kostiukova EG. Aripiprazole as an augmentation agent in ineffective antidepressant medication of patients with major depressive disorder. Sotsial’naia i klinicheskaia psikhiatriia. 2010;20(3):100-105. (In Russ.).
25. Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017;15(8):1192. doi: https://doi.org/10.2174/1570159X15666170413115754
26. JA Liberman. Chastichnye agonisty dofamina - novyi klass antipsikhotikov. Sotsial’naia i klinicheskaia psikhiatriia. 2007;17(1):61-66. (In Russ.).
27. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;(28):53-67. doi: https://doi.org/10.1016/S0306-4530(02)00112-9
28. Pigato G, Piazzon GVM, Di Florio A, et al. Early hyperprolactinaemia in acute psychiatric inpatients: A cross-sectional study. J Psychopathol. 2015;(21):226-230.
29. Ivanova SA, Osmanova DZ, Boiko AS, et al. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr Res. 2017;182:110-114. doi: https://doi.org/10.1016/j.schres.2016.10.029
30. Fedorenko OY, Loonen AJM, Vyalova NM, et al. Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia. Physiol Pharmacol. 2017;(21):25-33.
31. Fedorenko OY, Paderina DZ, Loonen AJM, et al. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia. Hum Psychopharmacol Clin Exp. 2020;35(4). doi: https://doi.org/10.1002/hup.2737
32. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193-203. doi: https://doi.org/10.1016/S0006-3223(02)01643-8
33. Schatzberg A.F., Nemeroff C.B. The American Psychiatric Association Publishing Textbook of Psychopharmacology, 4th Ed. American Psychiatric Association Publishing; 2009.
34. Stupak II, Lakhno IV. Regulatory mechanisms of prolactin biological effects realization (review). Vestnik Khar’kovskogo natsional’nogo universiteta imeni V.N. Karazina. 2006;12(720):156-161. (In Russ.).
35. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152(1):122-125. doi: https://doi.org/10.1176/ajp.152.1.122
36. Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl). 1998;137(2):201-202. doi: https://doi.org/10.1007/s002130050610
37. Akhkubekova NK. Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion. Problems of Endocrinology. 2009;55(6):46-48. (In Russ.). doi: https://doi.org/10.14341/probl200955646-48
38. Kamal TJ, Molitch ME. Effects of calcium channel blockade withverapamil on the prolactin responsesto TRH, L-Dopa, and bromocriptine. Am J Med Sci. 1992;304(5):289-293. doi: https://doi.org/10.1097/00000441-199211000-00004
39. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057. doi: https://doi.org/10.4065/80.8.1050
40. Lychkova AE, Puzikov AM. Prolaktin i serotonin. Vestnik RAMN. 2014;69(1-2):38-45. (In Russ.).
41. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict. 1995;30(8):919-927. doi: https://doi.org/10.3109/10826089509055820
42. Johnston LD, Miech RA, O’Malley PM, et al. Monitoring the Future national survey results on adolescent drug use 1975-2021: Overview, key findings on adolescent drug use. Inst Soc Res. 2022.
43. Coronas R, Cobo J, Gimenez-Palop O, et al. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf. 2012;7(2):92-98. doi: https://doi.org/10.2174/157488612802715753
44. Miyamoto BE, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015;45(5):266-272. doi: https://doi.org/10.3928/00485713-20150501-09
45. Yilanli M. 5 Strategies for managing antipsychotic-induced hyperprolactinemia. Curr Psychiatr. 2018;17(10):52-53.
46. Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;(45):25-34. doi: https://doi.org/10.1016/j.yfrne.2017.02.003
47. Holt RIG, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141-147. doi: https://doi.org/10.1111/j.1365-2265.2010.03814.x
48. Walters J, Jones I. Clinical questions and uncertainty — prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008;22(S2):82-89. doi: https://doi.org/10.1177/0269881107086516
49. Miyamoto BE, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015;45(5):266-272. doi: https://doi.org/10.3928/00485713-20150501-09
50. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs. 2004;64(20):2291-2314. doi: https://doi.org/10.2165/00003495-200464200-0000
51. Gao J, Liu Y, Han G, et al. Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. J Cell Mol Med. 2018;22(12):6368-6379. doi: https://doi.org/10.1111/jcmm.13963
Supplementary files
|
|
1. Figure 1. Schematic representation of the mechanisms of development of drug-induced hyperprolactinemia. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(344KB)
|
Indexing metadata ▾ | |
Review
For citations:
Dzeranova L.K., Vorotnikova S.Y., Shutova A.S., Pigarova E.A., Yevloyeva M.I. Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment. Obesity and metabolism. 2023;20(3):251-258. (In Russ.) https://doi.org/10.14341/omet13036
Views:
52005
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
